Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Chemotherapy
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- 71
Summary
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Patients with advanced HER2 positive breast cancer who had received at least paclitaxel, trastuzumab and TKIs (lapatinib or Pyrotinib) at least in the past were included in this study,Efficacy and safety of combination of inetetamab and PD-1 inhibitor combined with chemotherapy (including albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine or aribrin).Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04681287
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Min Yan Henan Cancer Hospital
Get Well Soon